ImageneBio Stock Forecast
NASDAQ: IMAHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
IMA analyst consensus
Consensus (4 analysts)
none
Avg. price target
$18.00+322.54%
- Strong buy 0
- Buy 3
- Hold 0
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 4 Wall Street analysts covering ImageneBio (2026-10-09), 3 rate the stock a buy or strong buy, 0 rate it a hold and 1 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $18.00, with a high estimate of $28.00 and a low estimate of $2.00. The average target implies upside of 322.5% from the current price of $4.26.
The spread between the highest and lowest targets is 1300.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for IMA.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 3 | 75% |
| Hold | 0 | 0% |
| Sell | 1 | 25% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-09.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $2.00 | -53.05% |
| Average target | $18.00 | +322.54% |
| High target | $28.00 | +557.28% |